Bayer HealthCare announced the launch of Finacea Foam (azelaic acid) 15% for the topical treatment of the inflammatory papules and pustules of mild to moderate rosacea. Finacea Foam was approved by the Food and Drug Administration (FDA) in July 2015.
The efficacy of Finacea Foam is driven by local mechanisms of azelaic acid within the skin. Its approval was based on data from two trials that studied the efficacy and safety of Finacea Foam vs. its foam vehicle (without azelaic acid) in the topical treatment of papulopustular rosacea. Finacea is already available as a gel formulation for the treatment of rosacea.
Each gram of Finacea Foam contains 0.15g (15% w/w) of azelaic acid. It is available as an emulsion in a pressurized 50g aluminum can.
For more information call (866) 463-3634 or visit FinaceaFoam.com.